Clinical trials using ABT-199 plus another anti-apoptotic member of the BCL2 family, a BH3 mimetic targeting myeloid cell leukemia sequence 1 (MCL1), are underway to extend the efficacy of ABT-199 in hematological malignancies. Here, BCL2 is linked to hematologic disorder.